- Home
- OPOF vs PROK Comparison
OPOF vs PROK Comparison
Compare OPOF & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPOF
- PROK
- Stock Information
- Founded
- OPOF 1922
- PROK 2015
- Country
- OPOF United States
- PROK United States
- Employees
- OPOF N/A
- PROK N/A
- Industry
- OPOF Major Banks
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPOF Finance
- PROK Health Care
- Exchange
- OPOF Nasdaq
- PROK Nasdaq
- Market Cap
- OPOF N/A
- PROK 126.8M
- IPO Year
- OPOF N/A
- PROK N/A
- Fundamental
- Price
- OPOF $29.94
- PROK $0.91
- Analyst Decision
- OPOF
- PROK Buy
- Analyst Count
- OPOF 0
- PROK 4
- Target Price
- OPOF N/A
- PROK $5.00
- AVG Volume (30 Days)
- OPOF 10.8K
- PROK 551.9K
- Earning Date
- OPOF 04-29-2025
- PROK 03-17-2025
- Dividend Yield
- OPOF 1.86%
- PROK N/A
- EPS Growth
- OPOF 22.03
- PROK N/A
- EPS
- OPOF 1.88
- PROK N/A
- Revenue
- OPOF $60,914,000.00
- PROK $76,000.00
- Revenue This Year
- OPOF N/A
- PROK N/A
- Revenue Next Year
- OPOF N/A
- PROK N/A
- P/E Ratio
- OPOF $15.99
- PROK N/A
- Revenue Growth
- OPOF 2.43
- PROK N/A
- 52 Week Low
- OPOF $13.49
- PROK $0.87
- 52 Week High
- OPOF $30.95
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- OPOF 61.40
- PROK 32.38
- Support Level
- OPOF $29.80
- PROK $0.87
- Resistance Level
- OPOF $30.21
- PROK $1.06
- Average True Range (ATR)
- OPOF 0.35
- PROK 0.10
- MACD
- OPOF -0.19
- PROK 0.01
- Stochastic Oscillator
- OPOF 51.04
- PROK 21.95
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.